Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1CNS 1

Conditions

Leukemia, Myeloid, Acute 246Precursor Cell Lymphoblastic Leukemia-Lymphoma 147Myelodysplastic Syndromes 141Leukemia, Lymphocytic, Chronic, B-Cell 140Leukemia 128Lymphoma 80Hematologic Neoplasms 77Lymphoma, Non-Hodgkin 73Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Hodgkin Disease 55Multiple Myeloma 54Myeloproliferative Disorders 37Recurrence 34Lymphoma, Mantle-Cell 29Graft vs Host Disease 28Burkitt Lymphoma 28Lymphoma, B-Cell 26Lymphoma, Follicular 25Leukemia, Biphenotypic, Acute 25Anemia, Refractory, with Excess of Blasts 23Leukemia, Myelomonocytic, Chronic 22Lymphoma, Large B-Cell, Diffuse 21Neoplasms, Plasma Cell 20Lymphoma, B-Cell, Marginal Zone 20Primary Myelofibrosis 19Leukemia, Prolymphocytic 14Leukemia, Myeloid 13Anemia, Aplastic 13Neoplasms 12Leukemia, B-Cell 12

Interventions

siltuximab 1fludarabine phosphate 1fludarabine 1Metoprolol 1Infliximab 1Etanercept 1Cyclophosphamide 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × fludarabine × Other hematologic neoplasm × Clear all
NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡